Pasireotide Diaspartate

Pasireotide Diaspartate Overview

Pasireotide (SOM230, trade name Signifor[2]) is an orphan drug approved in the United States[3] and Europe[4] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.[5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Pasireotide was approved for Cush...

Read more Pasireotide Diaspartate Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pasireotide

Recent Pasireotide Diaspartate Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pasireotide Diaspartate

For Suspension: 10mg/vial, 20mg/vial, 30mg/vial, 40mg/vial, 60mg/vial
Injection: 0.3mg/1ml, 0.6mg/1ml, 0.9mg/1ml
Powder: 20mg/vial, 40mg/vial, 60mg/vial
Solution: 0.3mg/ml (0.3mg/ml), 0.6mg/ml (0.6mg/ml), 0.9mg/ml (0.9mg/ml)
Suspension: 20mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Pasireotide Diaspartate or a similar ingredient: (2 results)

SIGNIFOR Pasireotide Diaspartate
SIGNIFOR LAR Pasireotide